Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Osteosarcoma
Stage/Subtype:  recurrent osteosarcoma
Trial Type:  Treatment
Results 1-25 of 26 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients with Metastatic Sarcoma Stable on Chemotherapy
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201309108, NCI-2013-01842, NCT01986829
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Cabozantinib-s-malate in Treating Patients with Relapsed Osteosarcoma or Ewing Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 9620, NCI-2014-01927, CABONE, NCT02243605
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Metastatic Soft Tissue and Bone Sarcomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14S03, NCI-2014-02583, STU00200112, NCT02357810
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Dinutuximab in Combination with Sargramostim in Treating Patients with Recurrent Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 29 and under
Trial IDs: AOST1421, NCI-2015-01001, NCT02484443
Glembatumumab Vedotin in Treating Patients with Recurrent or Refractory Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 49 years
Trial IDs: AOST1521, NCI-2015-01037, NCT02487979
Denosumab in Treating Patients with Recurrent or Refractory Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 11 to 49
Trial IDs: AOST1321, NCI-2015-00543, NCT02470091
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Recurrent Osteosarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 to 40
Trial IDs: 15-096, NCI-2015-01423, NCT02502786
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
HER2-Specific T Cells in Treating Patients With HER2-Positive Refractory or Metastatic Sarcoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: HEROS, NCI-2012-00634, NCT00902044
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 20 years
Trial IDs: SPOC-2012-001, NCI-2014-02681, NCT02013336
T Cell Receptor Gene Therapy in Treating Younger Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 35 and under
Trial IDs: 14-C-0059, NCI-2014-02506, P131369, NCT02107963
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Proton Beam Radiation Therapy in Treating Younger Patients with Bone or Non-rhabdomyosarcoma Soft Tissue Sarcomas
Status: Active
Phase: No phase specified
Type: Treatment
Age: 30 and under
Trial IDs: 05-326, NCI-2012-00673, NCT00592293
Start Over